CLL resource hub

CLL resources & codes

Dose Modifications* for ARs: An APP Perspective

Lisa Nodzon, PhD, ARNP, AOCNP discusses IMBRUVICA® dose modifications guidance for certain ARs and her perspective based on real-world experience.
See dose modifications for ARs
and data

Includes discontinuation.

Watch the video

IMBRUVICA® Long-Term Follow-Up Data Video

Hear Lisa Nodzon, PhD, ARNP, AOCNP, discuss data, including the long-term follow-up data, for IMBRUVICA®.
See the data, including, long-term follow-up data

Watch the video

IMBRUVICA® Dosing Video

Dosing information and outcomes data in patients with 1L CLL following dose modifications for ARs.

Watch the video

Primary & Long-Term Safety & Efficacy Brochure

Analysis of the open-label Phase 3 RESONATE™-2 trial with up to 10 years of follow-up data.
See the RESONATE™-2 data

Dose Modification Flashcard

Quick reference explaining how to modify IMBRUVICA® dosing to help manage ARs for patients with CLL.
See the dose modification data

Other IMBRUVICA® resources

By Your Side Program Page

IMBRUVICA® By Your Side provides access assistance, educational resources, and ongoing support to all eligible IMBRUVICA® patients and caregivers, regardless of insurance type or language preference.

Specialty Pharmacies & Distributors List

List of specialty pharmacies and distributors, along with their contact information.
Visit the Specialty Pharmacy & Distributor page

Additional IMBRUVICA® resource hubs

Abbreviation

AR=adverse reaction.